Bavarian Nordic has initiated two Phase III clinical trials of its mpox vaccine, Jynneos, in pregnant and breastfeeding women ...

Sale prices for the vouchers – which slash FDA review times for a drug – have increased in the past year as biotech funding dries up.

The FDA approval of Vimkunya has given the chikungunya vaccine’s owner, Bavarian Nordic, an extra financial windfall. | The ...

Danish biotech firm Bavarian Nordic could ramp up production of its mpox vaccine even before having orders lined up, based on the outcome of talks this week with the World Health Organisation, the ...

Bavarian Nordic is talking to other manufacturers that could produce more doses, but that, too, generally takes at least four to six months, Mr. Chaplin said. Image.

The WHO’s declaration of an emergency has caused Bavarian Nordic’s shares to jump over 40%. The company's shares are up 51% since the start of the year, with its market cap at $3.28 billion.

Fortune Europe Inside Bavarian Nordic: The $3.3 billion Danish vaccine maker with the world's only cure for mpox Forbes Mpox Vaccine Maker’s Shares Continue Rising As Concern Over Virus Outbreak ...

Bavarian Nordic CEO Paul Chaplin told STAT that 2 million doses of Jynneos vaccine could be produced this year, 8 million in 2025, to protect against mpox. Skip to Main Content.

Bavarian Nordic is also in talks to potentially expand production capacity. Bavarian has annual production capacity of 30 million doses, including the monkeypox vaccine and other vaccines it makes.

Bavarian Nordic has entered into contracts worth $1.2 billion with US Government. IMVAMUNE is a non-replicating small pox vaccine as is used for people who cannot use replicating small pox ...

Danish biotech firm Bavarian Nordic said on Tuesday it will donate 40,000 doses of its mpox vaccine to Africa's top public health body, after the body declared an emergency.

BAVARIAN NORDIC (BVNRY) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates ...